文献速递慢性肾脏病急性肾损伤

不确定潜能克隆性造血与CKD进展

Clonal Hematopoiesis of Indeterminate Potential and Progression of CKD.
PubMed 文献 · J Am Soc Nephrol · 2025-04-09

该研究在四个CKD队列(N=5654)中分析不确定潜能克隆性造血(CHIP)与CKD进展的关系,并通过腺嘌呤诱导的Tet2-CHIP小鼠模型评估肾脏功能和病理。Meta分析显示非DNMT3A CHIP与CKD进展风险升高64%相关(HR 1.64,95%CI 1.00-2.68),且eGFR下降更快;小鼠模型支持Tet2-CHIP对肾损伤的因果作用。

要点

  • 非DNMT3A CHIP与CKD进展风险升高独立相关(HR 1.64,95%CI 1.00-2.68)。
  • 基线eGFR 30-60 ml/min per 1.73 m2者效应最强(HR 1.85,95%CI 1.18-2.90)。
  • Tet2-CHIP小鼠模型出现更低GFR及更重炎症、小管损伤和纤维化。

核心结论

  • 非DNMT3A CHIP与CKD患者CKD进展相关,Tet2-CHIP小鼠模型支持其在肾损伤中的因果作用。

研究设计与样本

  • 研究纳入四个CKD队列共5654例个体(CRIC、AASK、BioVU、CanPREDDICT),分析CHIP与CKD进展及eGFR斜率。
  • 另采用饮食腺嘌呤诱导的Tet2-CHIP小鼠CKD模型评估肾脏功能和病理。

主要发现

  • 全部队列平均年龄66±11岁,平均基线eGFR 43±15 ml/min per 1.73 m2,24%存在CHIP。
  • Meta分析显示非DNMT3A CHIP与CKD进展风险升高64%相关(HR 1.64;95%CI 1.00-2.68)。
  • 基线eGFR 30-60 ml/min per 1.73 m2者效应最强(HR 1.85;95%CI 1.18-2.90)。
  • 非DNMT3A CHIP携带者eGFR下降更快(β −0.62±0.28 ml/min per 1.73 m2 per year;P=0.03)。
  • 腺嘌呤CKD小鼠模型中Tet2-CHIP与更低GFR及更重肾脏炎症、小管损伤和肾小管间质纤维化相关。

临床怎么用

  • 对CKD患者,尤其基线eGFR 30-60 ml/min per 1.73 m2者,检测非DNMT3A CHIP可能有助于识别CKD进展高风险人群。

局限性

  • CHIP在CKD人群中既往研究样本量有限且结果不一致,本研究为观察性关联分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: Non-DNMT3A clonal hematopoiesis of indeterminate potential was associated with CKD progression in a meta-analysis of 5654 individuals with CKD. In an adenine-induced CKD mouse model, Tet2-clonal hematopoiesis of indeterminate potential was linked to lower GFR, increased kidney inflammation, tubular injury, and fibrosis. BACKGROUND: Clonal hematopoiesis of indeterminate potential (CHIP) is a common inflammatory condition of aging that causes myriad end-organ damage. CHIP has been associated with incident AKI and kidney function decline in the general population, particularly mutations in CHIP genes other than DNMT3A (termed non-DNMT3A CHIP). Previous studies of CHIP in individuals with CKD had limited sample sizes and conflicting findings. METHODS: We examined CHIP and CKD progression in four CKD cohorts (N=5654): the Chronic Renal Insufficiency Cohort, the African American Study of Kidney Disease, individuals with CKD from the BioVU biorepository, and the Canadian Study of Prediction of Death, Dialysis and Interim Cardiovascular Events. Primary outcomes were incident CKD progression (50% eGFR decline or kidney failure) and eGFR slope over time. In addition, kidney function and pathology were assessed in a Tet2-CHIP mouse model of CKD induced by dietary adenine. RESULTS: Across all cohorts, the average age was 66±11 years, with an average baseline eGFR of 43±15 ml/min per 1.73 m2, and 24% had CHIP. After meta-analysis, non-DNMT3A CHIP was associated with a 64% higher relative risk of incident CKD progression (hazard ratio, 1.64; 95% confidence interval, 1.00 to 2.68), with the strongest effect observed in individuals with baseline eGFR 30–60 ml/min per 1.73 m2 (hazard ratio, 1.85; 95% confidence interval, 1.18 to 2.90). Non-DNMT3A CHIP carriers also exhibited a faster eGFR decline (β, −0.62±0.28 ml/min per 1.73 m2 per year; P = 0.03). In a dietary adenine mouse model of CKD, Tet2-CHIP was associated with lower GFR as well as greater kidney inflammation, tubular injury, and tubulointerstitial fibrosis. CONCLUSIONS: Non-DNMT3A CHIP was associated with CKD progression among individuals with CKD. Furthermore, Tet2-CHIP mouse models support a causal role in kidney injury.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Vlasschaert C, Pan Y, Chen J, et al. Clonal Hematopoiesis of Indeterminate Potential and Progression of CKD. J Am Soc Nephrol. 2025. PMID: 40202794. doi:10.1681/ASN.0000000680

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。